文献速递消化道肿瘤与早癌消化内镜

呼气挥发性有机化合物可作为结直肠进展期腺瘤与癌症的无创诊断生物标志物

Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer.
PubMed 文献 · Aliment Pharmacol Ther · 2019-12-20

这项多中心研究纳入接受结肠镜检查的成人患者,用电子鼻分析呼气挥发性有机化合物(VOCs),以评估其检测结直肠癌(CRC)和进展期腺瘤(AA)的能力。最终模型检测CRC的AUC为0.84(敏感度95%、特异度64%),检测AA的AUC为0.73(敏感度79%、特异度59%)。提示呼气VOCs有望成为无创诊断标志物。

要点

  • 呼气VOCs电子鼻检测CRC的最终模型AUC为0.84,敏感度95%、特异度64%。
  • 检测进展期腺瘤的最终模型AUC为0.73,敏感度79%、特异度59%。
  • 训练模型盲法验证CRC的AUC为0.74,AA的AUC为0.61。

核心结论

  • 呼气VOCs可能作为检测结直肠癌和进展期腺瘤的无创生物标志物。
  • 未来纳入更多患者的研究可进一步提升VOC分析对结直肠(前)恶性病变的判别能力。

研究设计与样本

  • 多中心研究,邀请无炎症性肠病或(既往)恶性肿瘤的成人结肠镜检查患者进行呼气分析。
  • 三分之二呼气试验随机分配用于开发训练模型,其余患者用于外部验证,最终全部数据用于开发最终疾病模型。

主要发现

  • 分类基于所发现的最进展病变:CRC 70例、进展期腺瘤117例、非进展期腺瘤117例、增生性息肉15例、结肠镜正常125例。
  • CRC和AA训练模型的AUC分别为0.76和0.71,盲法验证的AUC分别为0.74和0.61。
  • CRC和AA最终模型的AUC分别为0.84(敏感度95%、特异度64%)和0.73(敏感度79%、特异度59%)。

临床怎么用

  • 呼气VOCs电子鼻检测有望作为结直肠癌和进展期腺瘤的无创筛查或辅助诊断手段。
  • 当前模型特异度有限,临床应用前需进一步优化并在更大样本中验证。

局限性

  • 研究为探索性,最终模型判别能力仍需未来纳入更多患者的研究进一步验证和提升。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colorectal cancer (CRC) is the third most common cancer diagnosis in the Western world. AIM: To evaluate exhaled volatile organic compounds (VOCs) as a non-invasive biomarker for the detection of CRC and precursor lesions using an electronic nose. METHODS: In this multicentre study adult colonoscopy patients, without inflammatory bowel disease or (previous) malignancy, were invited for breath analysis. Two-thirds of the breath tests were randomly assigned to develop training models which were used to predict the diagnosis of the remaining patients (external validation). In the end, all data were used to develop final-disease models to further improve the discriminatory power of the algorithms. RESULTS: Five hundred and eleven breath samples were collected. Sixty-four patients were excluded due to an inadequate breath test (n = 51), incomplete colonoscopy (n = 8) or colitis (n = 5). Classification was based on the most advanced lesion found; CRC (n = 70), advanced adenomas (AAs) (n = 117), non-advanced adenoma (n = 117), hyperplastic polyp (n = 15), normal colonoscopy (n = 125). Training models for CRC and AAs had an area under the curve (AUC) of 0.76 and 0.71 and blind validation resulted in an AUC of 0.74 and 0.61 respectively. Final models for CRC and AAs yielded an AUC of 0.84 (sensitivity 95% and specificity 64%) and 0.73 (sensitivity and specificity 79% and 59%) respectively. CONCLUSIONS: This study suggests that exhaled VOCs could potentially serve as a non-invasive biomarker for the detection of CRC and AAs. Future studies including more patients could further improve the discriminatory potential of VOC analysis for the detection of (pre-)malignant colorectal lesions. (https://clinicaltrials.gov Identifier NCT03488537).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. van Keulen KE, Jansen ME, Schrauwen RWM, et al. Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer. Aliment Pharmacol Ther. 2019. PMID: 31858615. doi:10.1111/apt.15622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。